---
aliases:
  - ü´Å Study Guide - Pulmonary Neoplasia
tags:
  - System-block/Respiratory
  - AI-gen
---

## ü´Å Study Guide: Pulmonary Neoplasia
### 1. **Classification of Tumours**
**Main categories:**
- **Primary vs Secondary (metastatic)**
- **Benign vs Malignant**
- **Lung tumours**:
    - **Non-small cell lung cancer (NSCLC)**:
        - _Squamous cell carcinoma (SCC)_
        - _Adenocarcinoma (AdenoCa)_
        - _Large cell carcinoma_
    - **Small cell lung cancer (SCLC)**
    - **Carcinoid tumours** (low-grade neuroendocrine)
- **Pleural tumours**:
    - _Mesothelioma_
- **Other tumours**:
    - _Sarcomas, lymphomas, myelomas, germ cell tumours_
**WHO Practical Classification:**
- First: **Benign or malignant?**
- Then: **Primary or secondary?**
- If primary: **Small cell or NSCLC?**
- NSCLC ‚Üí Squamous vs Adenocarcinoma
- **Determine molecular signature** (guides treatment)
---
### 2. **Epidemiology**
- **#1 cause of cancer death** (men & women)
- **5th most common** in incidence
- Lifetime risk: ~5%
- **Mortality decreasing**, especially in developed countries
- **Incidence increasing**, especially in women
---
### 3. **Aetiology**
**Smoking** is the leading cause:
- 80% in current/former smokers
- **60x ‚Üë risk** in heavy smokers
- **Only ~10-15% of smokers develop cancer**
- Other risk factors:
    - **Asbestos** (5x ‚Üë risk; 55x ‚Üë if also smoking)
    - Radiation, air pollution, industrial exposures
    - Genetic factors (e.g. **TP53**, **EGFR**, **ALK**, **KRAS**)
**Never-smokers:**
- 5% of cases
- Often **adenocarcinoma**
- EGFR mutations common (targetable)
---
### 4. **Pathogenesis**
**Knudson‚Äôs hypothesis**: multiple non-lethal mutations ‚Üí cancer
- Types of gene mutations:
    - **Tumour suppressors (e.g. TP53)**
    - **Oncogenes (e.g. KRAS)**
    - **RTK mutations (e.g. EGFR, ALK)**
    - **Epigenetic/Environmental influences**
**Precursor lesions:**
- **SCC**: squamous metaplasia ‚Üí dysplasia ‚Üí carcinoma in situ ‚Üí invasive
- **AdenoCa**: AAH ‚Üí adenocarcinoma in situ ‚Üí invasive adenoCa
---
### 5. **Histological Subtypes**
|Subtype|Key Features|
|---|---|
|**Adenocarcinoma**|Peripheral, common in non-smokers & women; EGFR, ALK mutations; various growth patterns (lepidic, acinar, papillary, solid)|
|**Squamous Cell Carcinoma**|Central, aggressive, cavitating lesion; keratinisation & intercellular bridges|
|**Large Cell Carcinoma**|Undifferentiated, lacks glandular or squamous features|
|**Small Cell Lung Cancer (SCLC)**|Central, aggressive, early metastasis, **not surgical**, treated with **chemoradiotherapy**, neuroendocrine features|
|**Carcinoid Tumour**|Low-grade neuroendocrine, <5%, younger patients, **good prognosis** if typical|
---
### 6. **Clinical Presentation**
**Local symptoms:**
- Cough, haemoptysis, breathlessness, hoarse voice
- Chest pain, recurrent infections
- Pancoast tumour ‚Üí Horner syndrome
**Metastatic symptoms:**
- Liver, brain, bone
**Paraneoplastic Syndromes** (esp. SCLC):
- **ADH** ‚Üí hyponatraemia
- **ACTH** ‚Üí Cushing‚Äôs
- **PTHrP** ‚Üí hypercalcaemia
- **Serotonin** ‚Üí carcinoid syndrome
- Neurological: Lambert-Eaton, neuropathies
---
### 7. **Diagnosis**
**Investigations:**
- Sputum cytology
- **Pleural fluid cytology**
- **CT-guided Fine Needle Aspirate**
- **Bronchoscopy** (EBUS FNA)
- Biopsy or surgical resection
- **Molecular testing**: EGFR, ALK, ROS1, KRAS, BRAF, RET, MET, NTRK, HER2
---
### 8. **Grading and Staging**
**Grading**: degree of resemblance to normal tissue
- **Lepidic** pattern = better prognosis
- **Solid** pattern = worse prognosis
**Staging (TNM system)**:
- T: Tumour size/invasion
- N: Lymph node involvement
- M: Metastasis
> ~40% of lung cancers are **Stage IV** at diagnosis
---
### 9. **Treatment Principles**
**Prevention:**
- Primary: don‚Äôt start smoking
- Secondary: smoking cessation support
- Tertiary: manage complications
**Treatment Modalities:**
- **Surgery** (early stage only)
- **Chemotherapy** (esp. SCLC)
- **Targeted therapy** (EGFR, ALK mutations)
- **Immunotherapy** (PD-1, PD-L1, esp. squamous NSCLC)
- **Radiotherapy** (for inoperable or metastatic)
- **Multidisciplinary team** management essential
---
### 10. **Pleural Neoplasms ‚Äì Mesothelioma**
**Cause:** **Asbestos**
- Latency: 20‚Äì40 years
- ‚Üë Risk in smokers
- **Ban in Australia: 2003**
**Pathology:**
- Infiltrative tumour encasing lung
- Histological types: **epithelioid**, **sarcomatoid**, **biphasic**
- Presents with chest pain, dyspnoea, **pleural effusion**
- Poor prognosis: **12‚Äì18 months**
**Epidemiology:**
- ~700 cases/year in Australia
- Median age ~70 years
- Still increasing, peak expected in 2030s
---
### 11. **Summary & Key Takeaways**
- Lung cancer = leading cause of cancer death
- Strong link to smoking and industrial exposure
- Key types: **SCLC vs NSCLC (AdenoCa, SCC, Large Cell)**
- Subtype & mutation status guide management
- Pleural cancers (e.g. mesothelioma) strongly linked to **asbestos**
- **Histology + molecular testing + staging = treatment plan**
- MDT care is standard
